THALES
11.6.2020 09:32:13 CEST | Business Wire | Press release
Thales will provide its SelTrac™ Communications Based Train Control (CBTC) signalling solution in South Korea, Turkey and China, after signing three urban rail signalling contracts. Despite the current Covid-19 pandemic, governments around the globe are committed to progressing forward with crucial public transportation developments and Thales’s technology will be an important part of these projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005010/en/
Incheon Metro, Line 2 Capacity Increase
Incheon Subway Line 2 is part of the overall Seoul Metropolitan Subway network, which is currently undergoing modernisation to improve the performance and reliability of the network.
Thales has signed a contract with DaeaTi, a leading Korean railway signalling technology player, to provide new signalling equipment for the Incheon Line 2 depot capacity increase, which will address the need to park the six new driverless trains safely. The trains will be delivered in 2021 with Thales’ Vehicle On Board Controller (VOBC) which were separately contracted with train contractor Woojin Ind in 2019. Since the start of revenue service of Incheon’s L2 metro in July 2016, passenger flow has doubled from 90,000 to 180,000 a day, prompting the need for six additional trains to cope with the increase.
Thales has been working with Incheon City and Incheon Transit Corporation since 2009 on the Incheon Line 2, focusing on better serving the public transit users of Incheon as their common goal.
Istanbul Metro, Line M10
The M10 Line will be the first metro line to the Sabiha Gokcen International Airport, the second busiest airport in Turkey, on the Asian side of Istanbul and will comprise 7.5km of track and four stations. Gülermak-YSE Joint Venture is the main project contractor, and Thales has been contracted by Çelikler Taahhut, a major construction company, to install their SelTrac™ CBTC system on the new M10 Line in Istanbul Turkey, connecting the Kaynarca district and the Sabiha Gokcen Airport. The M4 line is already equipped with Thales’s SelTrac™ solution and the new contract will extend the existing technology onto the new line.
Upon completion, the new line will allow connectivity between the Airport and major cities, taking 13 minutes from the airport to Kaynarca, 46 minutes to Kadikoy and an hour to Yenikapı, on the European side. This project is part of the Government of Turkey’s key priorities to improve transportation in major cities , with a strong focus on connectivity between transportation hubs.
Nanchang Metro, Line 4
Thales SEC Transportation System Company Limited (TST), Thales’ Joint Venture with Shanghai Electric, will provide the signalling for the first phase of the new metro Line 4 in Nangchang, the capital and largest city of the Jiangxi Province in eastern China. The first phase of the Nanchang Metro Line 4 will expand from Baimashan Station to Yuweizhou Station, passing through the main area of Nanchang to connect five districts. The first phase of the Nanchang Metro Line 4 has a total operational length of 39.6km, with 34.1km underground, 5.5km elevated and 29 stations, making it the longest metro line in Nanchang, with the largest number of stations. .
TST is familiar with the network as they have previously delivered signalling systems to the Line 1 and Line 2 of the Nangchang Metro. This project will allow the Nanchang Metro to continue to support the rapidly growing population of Nanchang.
In parallel in China, on April 23rd, Hangzhou Metro Line 16, connecting Hangzhou downtown with Lin’an District, entered into revenue service smoothly. This very fast metro line relies on Thales SEC Transport signalling system technologies for maximum safety and efficiency, ensuring everyday pleasant and reliable journeys for local passengers and showing Thales commitment to China ground transportation.
“During the Covid-19 period, we are continuing to work together with our global partners in major cities such as Incheon, Istanbul, and Nanchang. Thales is committed to providing state-of-the-art SelTrac™ CBTC signalling technology. No matter the network or city, we continue to tailor our solution to meet the needs of the customer and provide reliable transportation solutions for their passengers.” – Dominique Gaiardo, Vice President and Managing Director for Thales’ urban rail signalling business.
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Transportation
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom